Boston Scientific Corp.’s (NYSE:BSX) cardiac rhythm management unit might be in a more pronounced slump than initially thought. Regulatory documents show that the company’s CRM business lost some significant ground during the first quarter. The Natick, Mass.-based medical device maker reported April 20 that sales for its CRM division, which makes pacemakers and implantable defibrillators, jumped 4 percent to $559 million during the first three months of 2011. But a closer look at the numbers reveals that BSX benefited more from a favorable comparison than a strong performance.
